This phase 2b/3 trial follows new, positive 2-year data from the phase 2 ALTITUDE trial, in which sura-vec was well-tolerated ...

The agreement is for a planned clinical trial of AXPAXLI (also known as OTX-TKI) for the treatment of non-proliferative ...

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...

The ADAPT study will evaluate the safety and effectiveness of the Calibreye surgical system in up to 70 patients with refractory glaucoma.

McDonald is clinical professor of ophthalmology at both NYU Langone Medical Center, New York, New York and Tulane University Health Sciences Center, New Orleans, Louisiana, and in practice with OCLI ...

Haller, MD, as new chief executive officer ...